{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 26 of 51', 'Study ID RCB: 2020-A00652-37', '9.3 Variables', \"The following data will be collected from the patients' medical records and reported on the\", 'CRF by the investigator.', 'Consent', 'Unique Study subject number (ISO three letter Country Code, followed by site number', 'within country and consecutive patient number within site)', 'Date of Informed Consent (dd.MMM.yyyy)', 'Date of first case report recording (dd.MMM.yyyy)', 'Demographics', 'Month/Year of Birth (MMM.yyyy)', 'Gender (Male/Female)', 'Weight (kg)', 'Height (cm)', 'Medical History', 'Date of diagnosis of psoriasis (dd.MMM.yyyy)', 'Location of Psoriasis (List: scalp, nail, body, joint involvement, genital or intimate', 'psoriasis, other)', 'Body Surface Area (xx%)', 'Commonly associated comorbidities (List: cardiovascular diseases, diabetes,', 'hypertension, depression, psoriasis arthritis, inflammatory bowel disease, other)', 'Smoking habits (never, active with pack years, not active with pack years and years', 'since stopped)', 'Alcohol consumption (never, occasionally or regularly with number of days/week,', 'number of drinks per day when alcohol is used)', 'Prior psoriasis treatment and posology + reason for discontinuation of the last therapy', 'administered', 'Standard occupational category.', 'Psoriasis treatments during study period', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 27 of 51', 'Study ID RCB: 2020-A00652-37', 'Study treatment & co-medications (product name, formulation, dose, number of', 'prescribed packages, package size)', 'Date of treatment initiation', 'Date of discontinuation (dd.MMM.yyyy)', 'Reason for discontinuation (noncompliance, adverse event, requirement for', 'alternative therapy, death, pregnancy, other)', 'Severity/effectiveness', 'Psoriasis area and severity index (PASI)', 'Patient Reported Outcome', 'Dermatology Life Quality Index (DLQI) score', 'PSO-TARGET QoL component grid', 'The collected data are presented in the following flow chart of the study :', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 28 of 51', 'Study ID RCB: 2020-A00652-37', 'Base-line', '3 months Visit', '12 months visit', 'Data to be collected', 'Visit (Day 0)', '(week 12-16)', '(week 48-56)', 'Unique Study subject', 'X', 'Month/Year of Birth', 'X', 'Gender', 'X', 'Weight', 'X', 'Height', 'X', 'Date of diagnosis', 'X', 'Location of Psoriasis', 'X', 'Body Surface Area', 'X', 'Commonly associated comorbidities', 'X', 'X', 'X', 'Smoking habits', 'X', 'Alcohol consumption', 'X', 'Prior psoriasis treatment', 'X', 'Psoriasis treatment during study period', 'X', 'X', 'X', 'Date of discontinuation of psoriasis treatment during study', 'X', 'X', 'period', 'Reason for discontinuation of psoriasis treatment during study', 'X', 'X', 'period', 'PASI', 'X', 'X', 'X', 'QoL component grid', 'X', 'X', 'X', 'DLQI', 'X', 'X', 'X', 'PSO-TARGET QoL component grid', 'X', 'X', 'X', '9.4 Data Source', 'Investigator will complete the CRF with assessments and information according to the', 'protocol. In addition, participants (patients) will be asked to enter data about their psoriasis', 'symptoms and their Quality of Life, during the data collection period.', 'The below described scores will be mandatory:', 'Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of', 'severity of psoriasis in clinical research. PASI combines the assessment of the severity', 'of lesions and the area affected into a single absolute score in the range 0 (no disease) to 72', '(maximal disease).', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 29 of 51', 'Study ID RCB: 2020-A00652-37', 'The Dermatology Quality of Life Index (DLQI) is well recognized Quality of Life questionnaire', 'in psoriasis and capture a combination of symptoms, impact on daily routines, and feeling of', 'stigmatization. It is a simple 10-question validated questionnaire that has been used in over', '40 different skin conditions in over 80 countries and is available in over 90 languages. Its use', 'has been described in over 1000 publications including many multinational studies. It is', 'recommended to provide indirect measure of disease severity and is well used in studies on', 'psoriasis and mentioned in the UK-treatment guideline (for details, see section 9.1.3).', 'The PSO-TARGET QoL component grid is a novel tool designed using a retrospective survey', \"based on the recollection and experience from 3 clinical dermatologists of patient's\", 'expectations. It contains 12 therapeutic goals equally distributed into the 4 major', 'psychometric components classically used in quality of life studies in patients suffering from', 'chronic diseases (Chassany, 2003; Forestier et al., 2019). These four dimensions are: physical,', 'subjective, relational/social and therapeutic. It has never been used before since it was', 'designed for the PSO-TARGET study. Each patient will be required to pick only one item in the', 'grid as his/her main therapeutic goal (see section 9.1.2). Treatment satisfaction in regards to', 'the chosen component will be assessed at 12/16 weeks and 52 weeks by a 4 points Likert Scale', 'and the level of concordance will be compared to DLQI scoring classes (described in section', '9.1.2).', '9.5 Study Size', 'The main criterion is the sensitivity of the PSO-TARGET tool (percentage of patients who', 'consider their target objective as being achieved after 12/16 weeks of treatment as defined', 'by a \"satisfied or very satisfied\" response, assessed on a 4 points Likert scale, among patients', 'with a DLQI total score of 0 or 1).', 'The sample size calculation is based on the following hypotheses:', 'Sensitivity: 90%', 'Absolute precision : 10%', 'Type I error : 5%', 'Power at 80%', 'Prevalence: 80% (estimated rate of patient with a DLQI 0-1 after 12 weeks of treatment)', 'Hypothesis :', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']", "completion": ""}